The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. (1st November 2016)

• Record Type: Journal Article
• Authors: Di Lorenzo, Giuseppe; De Placido, Sabino; Pagliuca, Martina; Ferro, Matteo; Lucarelli, Giuseppe; Rossetti, Sabrina; Bosso, Davide; Puglia, Livio; Pignataro, Piero; Ascione, Ilaria; De Cobelli, Ottavio; Caraglia, Michele; Aieta, Michele; Terracciano, Daniela; Facchini, Gaetano; Buonerba, Carlo; Sonpavde, Guru
• Is Part Of: Expert opinion on biological therapy. Volume 16:Number 11(2016:Nov.)
• Page Start: 1387
• Page End: 1401
• Publication Date: 2016-11-01
• Subjects: Kidney neoplasm -- monoclonal antibodies -- targeted therapy -- bevacizumab -- nivolumab; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2016.1216964
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction : While the majority of the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors currently used for the therapy of metastatic renal cell carcinoma (mRCC) are small molecule agents inhibiting multiple targets, monoclonal antibodies are inhibitors of specific targets, which may decrease off-target effects while preserving on-target activity. A few monoclonal antibodies have already been approved for mRCC (bevacizumab, nivolumab), while many others may play an important role in the therapeutic scenario of mRCC. Areas covered : This review describes emerging monoclonal antibodies for treating RCC. Currently, bevacizumab, a VEGF monoclonal antibody, is approved in combination with interferon for the therapy of metastatic RCC, while nivolumab, a Programmed Death (PD)-1 inhibitor, is approved following prior VEGF inhibitor treatment. Other PD-1 and PD-ligand (L)-1 inhibitors are undergoing clinical development. Expert opinion : Combinations of inhibitors of the PD1/PD-L1 axis with VEGF inhibitors or cytotoxic T-lymphocyte antigen (CTLA)-4 inhibitors have shown promising efficacy in mRCC. The development of biomarkers predictive for benefit and rational tolerable combinations are both important pillars of research to improve outcomes in RCC.